"Designing Growth Strategies is in our DNA"
In July 2018, ThromboGenics, Belgium based biotechnology company completed its first clinical trial of an antibody (THR-317) for the treatment of macular edema. Macular edema is an ophthalmic condition where the fluid builds up in the macula, an area in the center of the retina. Retina refers to the light-sensitive tissue or the sensory membrane that lines the inner layer at the back of the eyeball.
Retina enables the conversion of the light signals the lens receives to neural signals and the sending of these signals to the brain for visual recognition. The macula is a small but crucial area and is positioned in the center of the retina, enabling the clearer sight of details of objects such as faces and text. Macular edema can be classified into two types: diabetic macular edema and cystoid edema.
To gain extensive insights into the market, Request for Customization
Macular Edema can be caused due to diabetes, uveitis, retinal vein occlusion, aging, hereditary diseases, toxicity, trauma and after the undertaking of cataract surgery. The symptoms of macular edema include wavy or blurred vision, double vision, floaters and may lead to blindness if left untreated. Macular edema can be treated in a number of ways such as management of blood sugar, surgical procedures, corticosteroid treatments and anti-VEGF injections amongst others.
The global macular edema treatment market is anticipated to grow, owing to a number of factors such as the increasing prevalence of eye disorders such as various forms of macular edema and increasing incidence of diabetes leading to a greater incidence of diabetes macular edema.
Moreover, increasing research & developments in treatment options, rising emphasis on preventive medical care through regular eye examinations and increasing awareness regarding eye health is anticipated to offer favorable environment for the growth of the global macular edema treatment market during the forecast period.
According to the Centres for Disease Control and Prevention (CDC), in 2015, an estimated 30.3 million Americans, or 9.4% of the population, had diabetes and out of which an estimated 1.25 million American children and adults were suffering from type 1 diabetes.
Some of the factors limiting the growth of the global macular edema treatment market are the lack of awareness of the disease and the treatment options.
Some of the major companies that are present in the global macular edema treatment market are F. Hoffmann-La Roche Ltd, Alimera Sciences, Inc., Allergan, Novartis AG, GlaxoSmithKline plc., and Bausch Health Companies Inc., and others.
· Diabetic Macular Edema
· Cystoid Macular Edema
By Treatment Type
· Anti-VEGF (Vascular Endothelial Growth Factor) Injections
· Anti-inflammatory Medications
By End User
· Ophthalmic Care Institutions
· Ambulatory Surgery Centres
· North America (USA and Canada)
· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
· Latin America (Brazil, Mexico and Rest of Latin America)
· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Among the segmentation, diabetic macular edema in the type segment is expected to hold significant share of the market owing to higher prevalence of diabetic macular edema. Additionally, Anti-VEGF injections among treatment type segment is projected to register significant CAGR owing to its higher adoption due to its efficiency in treating macular edema.
North America is projected to dominate the global macular edema treatment market due to the increasing prevalence of ophthalmic diseases such as macular edemas, established healthcare system, high healthcare expenditure, and access to advanced technologies. The Asia Pacific is to exhibit the fastest emerging market due to increasing incidence and awareness of ophthalmic disorders and increasing access to advanced technologies. Combined with this, increasing patient population, gradual shift of patients towards early disease diagnosis and growing per capita expenditure in emerging nations are expected to offer a significant environment for the growth of the macula edema market in the Asia Pacific.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry